Adage Capital Partners
AARD

Adage Capital Partners’s Aardvark Therapeutics AARD Stock Holding History

Adage Capital Partners’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.13M Buy
+300,000
New +$3.11M ﹤0.01% 867
2025
Q4 		– Sell
-350,000
Closed -$4.65M – 1037
2025
Q3 		$4.65M Buy
350,000
+175,000
+100% +$1.97M 0.01% 743
2025
Q2 		$2.37M Sell
175,000
-75,000
-30% -$773K ﹤0.01% 756
2025
Q1 		$1.88M Buy
+250,000
New +$2.81M ﹤0.01% 763

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Adage Capital Partners's AARD Position: Q1 2026 in Review

Adage Capital Partners opened a new position in Aardvark Therapeutics (AARD) in Q1 2026: 300,000 shares worth $1.13M. The stake represents ﹤0.01% of the portfolio and ranks #867 among its holdings. This is a return to the name: Adage Capital Partners previously reported a position in AARD as recently as Q3 2025.

Adage Capital Partners first reported a position in AARD in Q1 2025 and has held it in 4 quarters since. The position peaked at $4.65M in Q3 2025. 79 funds tracked by Wall St. Rank hold AARD as of Q1 2026.

  • Adage Capital Partners held 300,000 shares of Aardvark Therapeutics worth $1.13M as of Q1 2026.
  • Aardvark Therapeutics was a new Adage Capital Partners position in Q1 2026.
  • Aardvark Therapeutics made up ﹤0.01% of Adage Capital Partners's portfolio in Q1 2026, its #867 holding.
  • Adage Capital Partners first reported a position in Aardvark Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • Adage Capital Partners's Aardvark Therapeutics position peaked at $4.65M in Q3 2025.
  • 79 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q1 2026.

Based on Adage Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.